
THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this circular.

If you are in any doubt as to any aspect of this circular or as to the action to be taken, you should consult your stockbroker or other registered dealer in securities, a bank manager, solicitor, professional accountant or other professional adviser.

If you have sold or transferred your shares in Cofoe Medical Technology Co., Ltd., you should at once hand this circular, together with the enclosed form of proxy, to the purchaser or transferee or to the bank, stockbroker or other agent through whom the sale or transfer was effected for transmission to the purchaser or transferee.



Cofoe Medical Technology Co., Ltd. **可孚醫療科技股份有限公司**

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1187)

REPURCHASE OF THE COMPANY'S A SHARES FOR CANCELLATION AND REDUCTION OF REGISTERED CAPITAL AMENDMENTS TO THE REMUNERATION MANAGEMENT RULES FOR DIRECTORS AND SENIOR MANAGEMENT AND NOTICE OF THE 2026 SECOND EXTRAORDINARY GENERAL MEETING

The notice convening the EGM to be held at Meeting Room 801, 8/F, Gaoqiao Big Health Medical Zone, No. 426, Section 1, Wanjiali Middle Road, Yuhua District, Changsha City, Hunan Province, the PRC on Friday, July 17, 2026 at 3:00 p.m. are set out on pages 23 to 25 in this circular.

The proxy form for use at the EGM was despatched to shareholders who have indicated their wish to receive a printed copy on Friday, June 26, 2026 and is also published on the websites of Hong Kong Stock Exchange (www.hkexnews.hk) and the Company (www.cfoe.com.cn). If you are unable to attend the EGM, please complete the proxy form in accordance with the instructions printed thereon and return it, together with the notarised power of attorney or other authorisation document, to the Company's H Share Registrar, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong (for holders of H Shares), as soon as practicable but in any event not less than 24 hours before the time appointed for the holding of the EGM. Completion and return of the proxy form will not preclude you from attending and voting in person at the EGM if you so wish.

This circular is prepared in both Chinese and English. In the event of any inconsistency between the Chinese and English versions, the Chinese version shall prevail.

June 26, 2026

CONTENTS

	<i>Page</i>
DEFINITIONS	1
LETTER FROM THE BOARD	3
APPENDIX – EXPLANATORY STATEMENT	17
NOTICE OF THE 2026 SECOND EXTRAORDINARY GENERAL MEETING	23

DEFINITIONS

In this circular, unless the context otherwise requires, the following terms shall have the following meanings:

“A Share(s)”	ordinary share(s) issued by the Company, with a nominal value of RMB1.00 each, which is/are subscribed for or credited as paid in Renminbi and is/are listed for trading on the Shenzhen Stock Exchange
“Articles of Association”	the Articles of Association of Cofoe Medical Technology Co., Ltd., as amended from time to time
“associate(s)”	has the meaning ascribed thereto under the Hong Kong Listing Rules
“Board” or “Board of Directors”	the board of Directors of the Company
“Company”	Cofoe Medical Technology Co., Ltd. (可孚醫療科技股份有限公司), a joint stock company with limited liability incorporated in the PRC, the H Shares of which are listed on the Main Board of the Hong Kong Stock Exchange (stock code: 1187) and the A Shares of which are listed on the Shenzhen Stock Exchange (stock code: 301087)
“Director(s)”	the director(s) of the Company
“EGM”	the 2026 second extraordinary general meeting of the Company to be convened to consider and, if thought fit, approve, among other matters, the repurchase of the Company’s A Shares for cancellation and reduction of registered capital, and the amendments to the Remuneration Management Rules for Directors and Senior Management
“H Shares”	ordinary shares issued by the Company, with a nominal value of RMB1.00 each, which are listed on the Hong Kong Stock Exchange and traded in Hong Kong Dollars
“H Share Registrar”	Tricor Investor Services Limited
“H Shareholder(s)”	holder(s) of H Shares
“Hong Kong”	the Hong Kong Special Administrative Region of the PRC
“Hong Kong Listing Rules”	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, as amended, supplemented or otherwise modified from time to time
“Hong Kong Stock Exchange”	The Stock Exchange of Hong Kong Limited

DEFINITIONS

“Latest Practicable Date”	June 22, 2026, being the latest practicable date prior to the printing of this circular for the purpose of ascertaining certain information referred to in this circular
“PRC”	the People’s Republic of China, and for the purpose of this circular only, excluding Hong Kong, the Macau Special Administrative Region of the PRC and Taiwan
“Share(s)”	the A Share(s) and/or H Share(s) of the Company
“%”	per cent

LETTER FROM THE BOARD



Cofoe Medical Technology Co., Ltd.

可孚醫療科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1187)

Executive Directors:

Mr. ZHANG Min (*Chairman*)
Mr. ZHANG Zhiming (*Vice chairman*)
Mr. XUE Xiaoqiao
Mr. HE Bangjie

Independent Non-executive Directors

Mr. NING Huabo
Ms. SHEN Nan
Mr. ZHOU Rong

Registered Office:

No. 87, Section 1, Huanbao East
Road
Yuhua District
Changsha City, Hunan Province
PRC

*Principal Place of Business in
Hong Kong, the PRC:*

Unit B, 22/F, Mai Luen Industrial
Building
23-31 Kung Yip Street
Kwai Chung, New Territories
Hong Kong, the PRC

June 26, 2026

To the Shareholders

Dear Sir/Madam,

**REPURCHASE OF THE COMPANY'S A SHARES FOR CANCELLATION AND
REDUCTION OF REGISTERED CAPITAL
AMENDMENTS TO THE REMUNERATION MANAGEMENT RULES
FOR DIRECTORS AND SENIOR MANAGEMENT
AND
NOTICE OF THE 2026 SECOND EXTRAORDINARY GENERAL MEETING**

I. INTRODUCTION

The purpose of this circular is to provide you, as H Shareholders, with the notice of the EGM set out on pages 23 to 25 of this circular and to provide you with such information as is reasonably necessary to enable you to make an informed decision as to whether to vote for or against or to abstain from voting on the resolutions to be proposed at the EGM.

LETTER FROM THE BOARD

The following special resolution will be proposed at the EGM to approve: (i) the repurchase of the Company's A Shares for cancellation and reduction of registered capital. In addition, an ordinary resolution will be proposed to approve: (ii) the amendments to the Remuneration Management Rules for Directors and Senior Management.

II. SPECIAL RESOLUTION

RESOLUTION ON THE REPURCHASE OF THE COMPANY'S A SHARES FOR CANCELLATION AND REDUCTION OF REGISTERED CAPITAL

The details of the repurchase of the Company's A Shares for cancellation and reduction of registered capital are summarised as follows:

(1) Purpose of the Repurchase of A Shares

Based on confidence in the Company's future development and recognition of the Company's value, and in order to effectively safeguard the interests of all shareholders and enhance investor confidence, and after comprehensive consideration of the Company's operating conditions, financial position, future profitability and reasonable valuation level, the Company proposes to repurchase part of its A Shares by way of centralized auction trading. The Shares repurchased will be cancelled in full and the registered capital of the Company will be reduced accordingly.

(2) The Repurchase of A Shares Meets Relevant Conditions

The repurchase by the Company meets the conditions set out in Article 10 of the Self-Regulatory Guideline for Companies Listed on the Shenzhen Stock Exchange No. 9 – Share Repurchase:

1. The Company's A Shares have been listed for at least six months;
2. The Company has no material illegal acts in the past year;
3. After the repurchase, the Company will have the ability to perform its debts and maintain its going-concern capability;
4. After the repurchase, the distribution of shareholding of the Company shall, in principle, comply with the listing requirements; if the Company intends to terminate the listing of its shares through the repurchase, it shall comply with the relevant provisions and obtain the consent of the Shenzhen Stock Exchange;
5. Other conditions stipulated by the China Securities Regulatory Commission and the Shenzhen Stock Exchange.

LETTER FROM THE BOARD

(3) Method and Price Range of the Proposed Repurchase of A Shares

1. Method of the proposed repurchase of A Shares

The Company will repurchase its A Shares by way of centralized auction trading.

2. Price range of the repurchase of A Shares

The repurchase price shall not exceed RMB69.66 per share (inclusive). The maximum repurchase price does not exceed 150% of the average trading price of the Company's A Shares in the 30 trading days prior to the Board's resolution approving the repurchase plan.

The actual repurchase price will be determined by the Company after the commencement of the repurchase, based on the specific circumstances of the Company's A Shares and in light of its financial and operating conditions. If the Company engages in any ex-dividend or ex-rights events such as dividend distributions, bonus share issuances or capitalizations of capital reserves during the repurchase period, the maximum repurchase price will be adjusted accordingly in accordance with the relevant requirements of the China Securities Regulatory Commission and the Shenzhen Stock Exchange from the ex-rights and ex-dividend date, and the Company shall perform its disclosure obligations.

(4) Type, Use, Quantity, Percentage of Total Share Capital of the Company and Total Funds to be Used for the Proposed Repurchase

1. Type of shares to be repurchased

The Company's issued RMB ordinary shares (A Shares).

2. Use of the proposed repurchase of A Shares

All A Shares repurchased will be cancelled and the registered capital will be reduced accordingly.

3. Quantity of A Shares to be repurchased, percentage of total share capital of the Company and total funds

The total funds to be used for the repurchase shall be no less than RMB100.00 million (inclusive) and no more than RMB200.00 million (inclusive). Based on the maximum repurchase price of RMB69.66 per share, the estimated number of A Shares to be repurchased is between 1,435,544 and 2,871,088 A Shares, representing approximately 0.61% to 1.22% of the Company's existing total share capital. The actual number and percentage of shares repurchased will be subject to the actual repurchase volume upon completion. If the Company engages in any ex-dividend or ex-rights events during the repurchase period, the maximum repurchase price and number of shares to be repurchased will be adjusted accordingly from the ex-rights and ex-dividend date.

LETTER FROM THE BOARD

(5) Source of Funds for the Repurchase of A Shares

The repurchase of A Shares will be financed by the Company's own funds and special loan funds for repurchase of A Shares, which are funds legally available for share repurchase under the Articles of Association, the Hong Kong Listing Rules and the applicable laws and regulations of the PRC. The repurchase of A Shares will not use the proceeds received from the issuance of H Shares.

Pursuant to the Notice on Matters Concerning the Establishment of a Relending Facility for Share Repurchase and Shareholding Increases jointly issued by the People's Bank of China, the National Financial Regulatory Administration and the China Securities Regulatory Commission, the Company is eligible for the share repurchase and shareholding increase relending facility. As of the date of this circular, the Company has obtained a Loan Commitment Letter from the Changsha Branch of China CITIC Bank Corporation Limited, pursuant to which the Changsha Branch of China CITIC Bank Corporation Limited has committed to provide the Company with a special loan facility for share repurchase in an amount not exceeding RMB180 million, with a loan term not exceeding three years. The specific loan arrangements will be subject to the loan contract to be entered into between the parties.

(6) Implementation Period of the Repurchase of A Shares

1. The implementation period of the repurchase of A Shares shall be 12 months from the date of consideration and approval of the Share repurchase plan at the shareholders' general meeting of the Company.
2. If any of the following conditions is triggered, the repurchase period will expire early:
 - (1) If, within the repurchase period, the number of A Shares repurchased or the amount of funds used for the repurchase reaches the maximum limit, the repurchase plan will be deemed fully implemented and the repurchase period will expire early from that date;
 - (2) If the Board decides to terminate the repurchase plan, the repurchase period will expire early from the date of the Board resolution to terminate the repurchase plan.
3. The Company shall not repurchase its A Shares during the following periods:
 - (1) From the date of occurrence of a material event that may have a significant impact on the trading price of the Company's securities and their derivatives, or during the decision-making process, until the date of disclosure in accordance with the law;
 - (2) Other circumstances stipulated by the China Securities Regulatory Commission and the Shenzhen Stock Exchange.

LETTER FROM THE BOARD

4. The Company's repurchase of A Shares by way of centralized auction trading shall comply with the following requirements:
 - (1) The bid price shall not be at the daily upper price limit of the Company's A Shares;
 - (2) Repurchase orders shall not be placed during the opening call auction, closing call auction, or on trading days when there is no price limit on the Company's A Shares on the Shenzhen Stock Exchange;
 - (3) Other requirements as stipulated by the China Securities Regulatory Commission and the Shenzhen Stock Exchange.
5. If, during the implementation of the repurchase plan, the Company's A Shares are suspended from trading for ten or more consecutive trading days due to the planning of major matters, the repurchase period may be extended accordingly, provided that such extension shall not exceed the maximum period prescribed by the China Securities Regulatory Commission and the Shenzhen Stock Exchange.

(7) Authorisation in Connection with the Implementation of the Repurchase of A Shares

To ensure the smooth implementation of the share repurchase, the Board proposes that the shareholders' general meeting authorise the Board, and the Board further authorise the Company's management, to handle the matters relating to the share repurchase within the scope permitted by laws and regulations and in accordance with the principle of maximising the protection of interests of the Company and its shareholders. The scope of authorisation includes but is not limited to:

- (1) Establishing a dedicated securities account for the repurchase and handling other related matters;
- (2) Repurchasing the Company's A Shares at an appropriate time within the repurchase period to the extent permitted by laws and regulations, including but not limited to the timing, price and quantity of implementation, and making corresponding adjustments in accordance with applicable laws, regulations and the Articles of Association;
- (3) In the event of any change in the regulatory policies regarding share repurchase or changes in market conditions, authorise the Board to make corresponding adjustments to the specific plan for share repurchase and other related matters, except for those matters that are required by applicable laws, regulations and the Articles of Association to be re-considered at the shareholders' general meeting;
- (4) Handling the relevant approval formalities, including but not limited to authorising, signing, executing, amending and completing all necessary documents, contracts and agreements relating to the share repurchase;

LETTER FROM THE BOARD

- (5) Adjusting the specific implementation plan in accordance with the relevant provisions, and handling other matters relating to the share repurchase and cancellation. Based on the actual situation of repurchase, handling all matters relating to the share repurchase and cancellation, as well as the amendments to the Articles of Association and industrial and commercial registration changes;
- (6) Handling other matters not specifically enumerated above but necessary for the share repurchase.

The above authorisation shall be valid from the date of approval of the repurchase plan at the shareholders' general meeting of the Company until the completion of all authorised matters.

This resolution was considered and approved by the Board on June 26, 2026 and is now submitted to the EGM for consideration and approval by way of a special resolution.

LETTER FROM THE BOARD

III. ORDINARY RESOLUTION

RESOLUTION ON THE AMENDMENTS TO THE REMUNERATION MANAGEMENT RULES FOR DIRECTORS AND SENIOR MANAGEMENT

Pursuant to the Corporate Governance Guidelines for Listed Companies and the relevant provisions of the Articles of Association, and in light of the actual situation of the Company, the Company has amended certain provisions of the Remuneration Management Rules for Directors and Senior Management. The comparison table before and after the amendment is set out as follows:

After amendment	Before amendment
<p>Article 4 The Company shall, based on the total wages of the previous year, make dynamic adjustments taking into account the Company's annual operating targets and performance, external market environment, industry remuneration levels, number of employees, input-output ratio of labour costs and other factors. Changes in total wages shall be linked to the Company's operating performance, so as to enhance the scientific, reasonable and effective determination of total wages.</p>	
<p>Article 5 The Remuneration and Appraisal Committee of the Board of the Company is the management body responsible for the remuneration and performance appraisal of the Directors and senior management of the Company. It is responsible for researching and formulating the appraisal standards, remuneration plans and remuneration policies for the Directors and senior management, and for organising the implementation of performance evaluations for the Directors and senior management.</p>	<p>Article 4 The Board of the Company is responsible for considering the remuneration of the Company's senior management, and the shareholders' general meeting of the Company is responsible for considering the remuneration of the Directors.</p>

LETTER FROM THE BOARD

After amendment	Before amendment
<p>Article 6 The remuneration plans for the Directors shall be determined by the shareholders' general meeting and disclosed. The remuneration plans for senior management shall be approved by the Board, explained to the shareholders' general meeting and fully disclosed. The remuneration plans for non-independent Directors and senior management and their implementation shall be supervised by the independent Directors of the Company. When the Board or the Remuneration and Appraisal Committee of the Board of the Company evaluates or discusses the remuneration of an individual Director, such Director shall recuse himself/herself.</p>	<p>Article 5 The Remuneration and Appraisal Committee of the Board of the Company, under the authorisation of the Board, is responsible for formulating the appraisal standards for the Directors and senior management, and for formulating and reviewing the remuneration plans and performance of the Directors and senior management.</p>
<p>Article 7 The human resources center and other functional departments of the Company shall cooperate with the Remuneration and Appraisal Committee of the Board in the implementation of specific remuneration plans for the Directors and senior management of the Company.</p>	<p>Article 6 The human resources center and other functional departments of the Company shall cooperate with the shareholders' general meeting and the Board in the implementation of specific remuneration plans for the Directors and senior management of the Company.</p>
<p>Article 8 The remuneration standards of non-independent Directors who hold positions in the Company or undertake operational management functions but do not concurrently serve as senior management shall be determined based on their positions and responsibilities in the Company. The remuneration standards of non-independent Directors who concurrently serve as senior management shall be implemented in accordance with the Company's remuneration standards for senior management.</p> <p>Independent Directors shall receive an allowance from the Company. The specific standard of the allowance shall be determined with reference to the standards of similar listed companies, and shall be submitted to the Board for discussion and approval, and then to the shareholders' general meeting for consideration and approval. External non-independent Directors who do not hold any actual working positions in the Company shall not receive remuneration from the Company.</p>	<p>Article 7 Remuneration or allowance of Directors of the Company</p> <p>(i) Independent Directors: Independent Directors shall receive an allowance from the Company. The specific standard of the allowance shall be determined with reference to the standards of similar listed companies, and shall be submitted to the Board for discussion and approval, and then to the shareholders' general meeting for consideration and approval.</p> <p>(ii) Non-independent Directors: Non-independent Directors who hold actual working positions in the Company shall receive remuneration in accordance with the Company's relevant remuneration standards and performance appraisal based on their actual positions in the Company, and shall not receive any additional Director's allowance. External non-independent Directors who do not hold any actual working positions in the Company shall not receive remuneration from the Company.</p>

LETTER FROM THE BOARD

After amendment	Before amendment
<p>Article 9 The basic remuneration of the Directors and senior management of the Company shall be determined based on their positions and performance of duties in the Company, with reference to the remuneration levels of similar or equivalent positions in the same industry and region. Performance-based remuneration and medium and long-term incentive income shall be determined based on performance evaluation, achievement of performance targets and in light of the Company’s annual operating performance. The remuneration of Directors and senior management of the Company who hold positions in the Company or undertake operational management functions shall consist of basic remuneration, performance-based remuneration and medium and long-term incentive income, among which the proportion of performance-based remuneration shall, in principle, be no less than 50% of the total of basic remuneration and performance-based remuneration.</p> <p>The remuneration of the Directors and senior management of the Company shall be aligned with market development, matched with the Company’s operating performance and individual performance, and coordinated with the Company’s sustainable development.</p>	<p>Article 8 Remuneration of senior management of the Company</p> <p>The remuneration of senior management of the Company consists of basic annual salary and performance bonus. (i) Basic annual salary: mainly determined based on personal position, responsibilities, capabilities, market salary levels and other factors, and paid monthly; (ii) Performance bonus: determined based on the Company’s operating performance and individual performance, and paid annually or monthly according to the appraisal results.</p>
<p>Article 14 The basic remuneration of Directors and senior management who concurrently hold positions in the Company (including concurrent positions as senior management or other positions) shall be paid monthly by the Company, and their performance-based remuneration shall be implemented in accordance with the remuneration plans for Directors and senior management approved by the Board or the shareholders’ general meeting of the Company.</p>	<p>Article 12 The timing and method of payment of remuneration for Directors and senior management who concurrently hold other positions in the Company shall be determined in accordance with the Company’s wage payment rules.</p>

LETTER FROM THE BOARD

After amendment	Before amendment
<p>Article 10 The remuneration and allowances of the Directors and senior management of the Company are pretax amounts. The Company shall deduct taxes, social insurance and other expenses in accordance with the relevant provisions of the state and the Company, and pay the remaining amount to the individuals.</p>	<p>Article 13 The remuneration or allowances of the Directors and senior management of the Company are pretax amounts, and the Company shall withhold and pay individual income tax in accordance with the relevant provisions of the state.</p>
<p>Article 15 The determination and payment of performance-based remuneration and medium and long-term incentive income of the Directors and senior management of the Company shall be based on performance evaluation as an important criterion. A certain proportion of the performance-based remuneration of the Directors and senior management of the Company shall be paid after the disclosure of the annual report and performance evaluation, and the performance evaluation shall be conducted based on audited financial data.</p>	
<p>Article 16 The performance evaluation of the Directors and senior management of the Company shall be organised by the Remuneration and Appraisal Committee of the Board, and the Company may engage a third party to carry out the performance evaluation. The performance evaluation of independent Directors shall be conducted by way of self-evaluation and mutual evaluation. The Board shall report to the shareholders' general meeting on the performance of duties, performance evaluation results and remuneration of the Directors, and the Company shall make disclosure thereof.</p>	

LETTER FROM THE BOARD

After amendment	Before amendment
<p>Article 18 If any of the following circumstances occurs during the term of office of a Director or senior management of the Company, the Company shall have the right, in light of the specific circumstances, not to pay or to reduce the performance-based remuneration and medium and long-term incentive income of such Director or senior management, and to recover, in whole or in part, the performance-based remuneration and medium and long-term incentive income already paid during the period in which the relevant conduct occurred:</p> <p>(i) being publicly censured by a stock exchange or declared as an unsuitable candidate;</p> <p>(ii) being subject to administrative penalties or administrative regulatory measures by the China Securities Regulatory Commission for material illegal or non-compliant acts;</p> <p>(iii) seriously violating the Company’s rules and regulations and being subject to internal disciplinary action;</p> <p>(iv) violating laws and regulations or committing dereliction of duty or misconduct, leading to major decision-making errors and causing serious impact on the Company;</p> <p>(v) seriously harming the interests of the Company and its holding subsidiaries;</p> <p>(vi) other circumstances determined by the Board or the Remuneration and Appraisal Committee of the Company to constitute a serious violation of the Company’s relevant provisions.</p>	

LETTER FROM THE BOARD

After amendment	Before amendment
<p>Article 19 If the Company incurs an operating loss, the changes in remuneration of Directors and senior management during the various approval stages shall be specifically explained as to whether they comply with the performance linkage requirements. If the Company turns from profit to loss or its loss widens compared with the previous financial year, and the average annual performance-based remuneration of Directors and senior management does not decrease accordingly, the reasons shall be disclosed.</p>	
<p>Article 20 When the Company restates its financial statements retrospectively due to misstatements such as financial fraud, the Company shall promptly reevaluate the performance-based remuneration and medium and long-term incentive income of the Directors and senior management and recover the excess portion accordingly.</p> <p>If a Director or senior management of the Company breaches his/her duties and causes losses to the Company, or is at fault for illegal or non-compliant acts such as financial fraud, fund misappropriation or unauthorised guarantees, the Company shall, depending on the severity of the circumstances, reduce or cease payment of unpaid performance bonuses and medium and long-term incentive income, and recover, in whole or in part, the performance bonuses and medium and long-term incentive income already paid during the period in which the relevant conduct occurred.</p>	<p>Article 16 If a Director or senior management of the Company breaches his/her duties and causes losses to the Company, or is at fault for illegal or non-compliant acts such as financial fraud, fund misappropriation or unauthorised guarantees, the Company shall, depending on the severity of the circumstances, reduce or cease payment of unpaid performance bonuses and medium and long-term incentive income, and recover, in whole or in part, the performance bonuses and medium and long-term incentive income already paid during the period in which the relevant conduct occurred.</p>

This resolution was considered and approved by the Board on June 26, 2026 and is now submitted to the EGM for consideration and approval by way of an ordinary resolution.

LETTER FROM THE BOARD

IV. EGM ARRANGEMENT

The Company will hold its 2026 second extraordinary general meeting at Meeting Room 801, 8/F, Gaoqiao Big Health Medical Zone, No. 426, Section 1, Wanjiali Middle Road, Yuhua District, Changsha City, Hunan Province, the PRC on Friday, July 17, 2026 at 3:00 p.m. The notice of the EGM is set out on pages 23 to 25 in this circular.

The register of members of H Shares of the Company will be closed from Tuesday, July 14, 2026 to Friday, July 17, 2026 (both days inclusive), during which no transfer of H Shares will be effected. Shareholders whose names appear on the register of members of H Shares of the Company on Friday, July 17, 2026 will be entitled to attend and vote on all resolutions to be proposed at the EGM. Holders of H Shares who wish to attend the EGM should lodge all transfer documents accompanied by the relevant share certificates with the H Share Registrar, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong, no later than 4:30 p.m. on Monday, July 13, 2026. The record date for determining the entitlement to attend and vote at the EGM will be Friday, July 17, 2026.

The proxy form for use at the EGM was despatched to shareholders who have indicated their wish to receive a printed copy on June 26, 2026. The proxy form is also published on the HKExnews website of the Hong Kong Stock Exchange (www.hkexnews.hk) and on the Company's website (www.cofoe.com.cn).

To be valid, the proxy form, together with the notarised power of attorney or other authorisation document, must be lodged with the H Share Registrar not less than 24 hours before the time appointed for the holding of the EGM (i.e., by 3:00 p.m. on Thursday, July 16, 2026). Completion and return of the proxy form will not preclude you from attending and voting in person at the EGM if you so wish.

V. PROVISIONS UNDER THE HONG KONG LISTING RULES

Pursuant to Rule 13.39(4) of the Hong Kong Listing Rules, except where the chairman, in good faith, decides to allow resolutions which are purely procedural or administrative in nature to be passed by a show of hands, any vote of shareholders at a general meeting must be taken by poll. Accordingly, all resolutions at the EGM will be taken by poll.

As of the Latest Practicable Date, to the best of the Directors' knowledge, no shareholder has a material interest in any of the above resolutions, and no shareholder is required to abstain from voting on the above resolutions at the EGM.

VI. RESPONSIBILITY STATEMENT

This circular, for which the Directors jointly and severally accept full responsibility, contains information given in compliance with the Hong Kong Listing Rules for the purpose of providing information about the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief, the information contained in this circular is accurate and complete in all material respects, is not misleading or deceptive, and there is no other matter the omission of which would make any statement in this circular or this circular misleading.

LETTER FROM THE BOARD

VII. RECOMMENDATION

The Board considers that the resolutions referred to above are in the best interests of the Company and the shareholders as a whole. Accordingly, the Board recommends that all Shareholders vote in favour of the relevant resolutions as set out in the notice of the EGM accompanying this circular at the EGM.

By order of the Board
Cofoe Medical Technology Co., Ltd.
ZHANG Min
Executive Director and Chairman of the Board

The following is an explanatory statement required to be sent to shareholders under Rule 10.06(1)(b) of the Listing Rules in connection with the A Share repurchase plan.

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this document, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this document.

REASONS FOR THE REPURCHASE

Based on confidence in the Company's future development and recognition of the Company's value, and in order to effectively safeguard the interests of all shareholders of the Company and enhance investor confidence, and after comprehensive consideration of operating conditions, financial position, future profitability and reasonable valuation level, the Company proposes to repurchase part of its A Shares by way of centralized auction trading. The A Shares repurchased will be cancelled in full and the registered capital of the Company will be reduced accordingly.

SHARE CAPITAL AND NUMBER OF A SHARES TO BE REPURCHASED

As at the Latest Practicable Date, the total issued share capital of the Company is 235,897,000 Shares, comprising 208,897,000 A Shares with a nominal value of RMB1.00 each and 27,000,000 H Shares with a nominal value of RMB1.00 each, of which 7,195,881 A Shares are treasury shares.

The total funds to be used for the repurchase shall be no less than RMB100.00 million (inclusive) and no more than RMB200.00 million (inclusive). Based on the maximum repurchase price of RMB69.66 per share, the estimated number of A Shares to be repurchased is between 1,435,544 and 2,871,088 A Shares, representing approximately 0.61% to 1.22% of the Company's existing total share capital. The actual number and percentage of A Shares repurchased will be subject to the actual repurchase volume upon completion. If the Company engages in any ex-dividend or ex-rights events during the repurchase period, the maximum repurchase price and number of A Shares to be repurchased will be adjusted accordingly from the ex-rights and ex-dividend date.

SHAREHOLDERS' APPROVAL

The A Share repurchase plan is subject to the passing of a special resolution at the EGM to be held on July 17, 2026.

1. The implementation period of the repurchase of A Shares shall be 12 months from the date of consideration and approval of the Share repurchase plan at the shareholders' general meeting of the Company.

2. If any of the following conditions is triggered, the repurchase period will expire early:
 - (1) If, within the repurchase period, the number of A Shares repurchased or the amount of funds used for the repurchase reaches the maximum limit, the repurchase plan will be deemed fully implemented and the repurchase period will expire early from that date;
 - (2) If the Board decides to terminate the repurchase plan, the repurchase period will expire early from the date of the Board resolution to terminate the repurchase plan.
3. The Company shall not repurchase its A Shares during the following periods:
 - (1) From the date of occurrence of a material event that may have a significant impact on the trading price of the Company's securities and their derivatives, or during the decision-making process, until the date of disclosure in accordance with the law;
 - (2) Other circumstances stipulated by the China Securities Regulatory Commission and the Shenzhen Stock Exchange.
4. The Company's repurchase of A Shares by way of centralized auction trading shall comply with the following requirements:
 - (1) The bid price shall not be at the daily upper price limit of the Company's A Shares;
 - (2) Repurchase orders shall not be placed during the opening call auction, closing call auction, or on trading days when there is no price limit on the Company's A Shares on the Shenzhen Stock Exchange;
 - (3) Other requirements as stipulated by the China Securities Regulatory Commission and the Shenzhen Stock Exchange.
5. If, during the implementation of the repurchase plan, the Company's A Shares are suspended from trading for ten or more consecutive trading days due to the planning of major matters, the repurchase period may be extended accordingly, provided that such extension shall not exceed the maximum period prescribed by the China Securities Regulatory Commission and the Shenzhen Stock Exchange.

SOURCE OF FUNDS FOR THE REPURCHASE

The repurchase of A Shares will be financed by the Company's own funds and special loan funds for repurchase of A Shares, which are funds legally available for share repurchase under the Articles of Association, the Hong Kong Listing Rules and the applicable laws and regulations of the PRC. The Company will not use any proceeds from the issuance of H Shares for the repurchase of A Shares.

Pursuant to the Notice on Matters Concerning the Establishment of a Relending Facility for Share Repurchase and Shareholding Increases jointly issued by the People's Bank of China, the National Financial Regulatory Administration and the China Securities Regulatory Commission, the Company is eligible for the share repurchase and shareholding increase relending facility. As of the date of this circular, the Company has obtained a Loan Commitment Letter from the Changsha Branch of China CITIC Bank Corporation Limited, pursuant to which the Changsha Branch of China CITIC Bank Corporation Limited has committed to provide the Company with a special loan facility for share repurchase in an amount not exceeding RMB180 million, with a loan term not exceeding three years. The specific loan arrangements will be subject to the loan contract to be entered into between the parties.

IMPACT ON WORKING CAPITAL

As of December 31, 2025 (audited), the Company's total assets were approximately RMB6,628,915,200, the owners' equity attributable to shareholders of the listed company was approximately RMB4,866,857,700, and current assets were approximately RMB3,835,321,700. Assuming the maximum repurchase amount of RMB200.00 million is fully utilised, and based on the financial data as at December 31, 2025, the repurchase funds would represent approximately 3.02% of the Company's total assets, approximately 4.11% of the owners' equity attributable to shareholders of the listed company, and approximately 5.21% of the Company's current assets. In light of the Company's current operating and financial conditions and its future development plans, the Company considers that utilising total funds of no less than RMB100.00 million and no more than RMB200.00 million for the share repurchase, which will be paid at appropriate times during the repurchase period and is therefore flexible, will not have a material impact on the Company's operations, financial position and future significant development.

Based on the maximum repurchase funds of RMB200.00 million and the maximum repurchase price of RMB69.66 per share, the estimated number of A Shares to be repurchased would represent approximately 1.22% of the Company's total issued share capital. Upon completion of the repurchase, the Company's shareholding structure would not change significantly. The distribution of shareholding of the Company continues to satisfy the listing conditions, and therefore the repurchase will not result in the Company failing to meet the listing requirements.

A SHARE AND H SHARE PRICES

The highest and lowest trading prices of the A Shares on the Shenzhen Stock Exchange and the H Shares on the Hong Kong Stock Exchange in each month during the 12 months preceding the Latest Practicable Date are set out below:

Month	Highest price of A Share	Lowest price of A Share	Highest price of H Share ^(Note)	Lowest price of H Share ^(Note)
	<i>RMB</i>	<i>RMB</i>	<i>HK\$</i>	<i>HK\$</i>
June 2025	34.41	32.08	–	–
July 2025	37.17	33.25	–	–
August 2025	42.64	37.50	–	–
September 2025	41.45	38.13	–	–
October 2025	45.70	38.49	–	–
November 2025	45.48	40.88	–	–
December 2025	46.04	43.20	–	–
January 2026	60.50	47.57	–	–
February 2026	57.75	51.21	–	–
March 2026	61.64	53.19	–	–
April 2026	57.22	53.02	–	–
May 2026	52.16	46.78	38.90	28.70
June 2026 (up to the Latest Practicable Date)	47.01	43.67	33.00	27.02

Note: The Company's H Shares were listed on the Main Board of The Stock Exchange of Hong Kong Limited on May 6, 2026 (the "**Listing Date**"). The highest and lowest prices of H Shares are calculated from the Listing Date.

SHARES REPURCHASED BY THE COMPANY

During the six months immediately preceding the Latest Practicable Date, the Company has repurchased 3,317,150 A Shares on the Shenzhen Stock Exchange.

	Date of repurchase	Number of A Shares repurchased	Price per A Share	
			Lowest price paid RMB	Highest price paid RMB
1.	April 15, 2026	202,000	55.846	57.746
2.	April 16, 2026	308,300	56.829	57.676
3.	April 17, 2026	107,100	56.141	57.386
4.	April 20, 2026	61,000	58.44	58.944
5.	April 21, 2026	235,600	56.50	58.33
6.	April 22, 2026	266,450	54.96	56.73
7.	April 23, 2026	145,200	53.469	55.04
8.	April 24, 2026	248,200	53.108	54.964
9.	April 27, 2026	159,500	54.02	55.067
10.	April 28, 2026	435,400	51.57	52.876
11.	April 29, 2026	552,900	52.467	53.972
12.	April 30, 2026	595,500	52.257	54.302

Save as disclosed above, the Company has not purchased, sold or redeemed any of its Shares (whether on the Stock Exchange or otherwise) during the six months immediately preceding the Latest Practicable Date.

DIRECTORS' UNDERTAKINGS AND GENERAL INFORMATION

The Directors will exercise the Company's powers to carry out the repurchase in accordance with the Listing Rules and the applicable laws, regulations and rules of the PRC, and in accordance with the authority granted by the shareholders at the EGM.

The Directors and, to the best of their knowledge and belief after making all reasonable enquiries, their close associates (as defined in the Listing Rules) do not currently intend to sell any Shares to the Company following the approval of the repurchase plan by the Shareholders at the EGM.

The Company has not received any notification from any core connected person (as defined in the Listing Rules) of the Company indicating that they currently intend to sell any Shares to the Company following the approval of the repurchase plan by the Shareholders at the EGM, nor have they undertaken not to sell any Shares held by them to the Company.

TAKEOVERS CODE AND PUBLIC FLOAT REQUIREMENTS

If the repurchase of Shares by the Company results in an increase in the proportion of voting rights of a substantial shareholder in the Company, such increase will be treated as an acquisition for the purposes of Rule 32 of the Takeovers Code. Accordingly, a shareholder or a group of shareholders acting in concert may obtain or consolidate control of the Company, or may be required to make a mandatory general offer under Rules 26 and 32 of the Takeovers Code.

If the repurchase would result in the public float falling below the prescribed minimum percentage as determined by the Stock Exchange, the Listing Rules prohibit the Company from repurchasing Shares on the Stock Exchange. The Directors do not intend to repurchase Shares such that the number of Shares held by the public would fall below the prescribed minimum percentage.

To the best of the Directors' knowledge, the repurchase of A Shares by the Company will not give rise to any other consequences under the Takeovers Code.

The Company confirms that there is nothing unusual about this explanatory statement or the proposed share repurchase.

STATUS OF THE REPURCHASED A SHARES

The A Shares repurchased by the Company will be dealt with in accordance with the relevant PRC laws and regulations and the Listing Rules, as applicable.

NOTICE OF THE 2026 SECOND EXTRAORDINARY GENERAL MEETING



Cofoe Medical Technology Co., Ltd.

可孚醫療科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1187)

NOTICE OF THE 2026 SECOND EXTRAORDINARY GENERAL MEETING

NOTICE IS HEREBY GIVEN that the 2026 second extraordinary general meeting (the “EGM”) of Cofoe Medical Technology Co., Ltd. (the “Company”) will be held at Meeting Room 801, 8/F, Gaoqiao Big Health Medical Zone, No. 426, Section 1, Wanjiashi Middle Road, Yuhua District, Changsha City, Hunan Province, the PRC on Friday, July 17, 2026 at 3:00 p.m., for the purpose of considering and, if thought fit, passing the following resolutions. Unless the context otherwise requires, terms used in this notice shall have the same meanings as defined in the circular of the Company dated June 26, 2026 (the “Circular”, of which this notice of the EGM forms part).

SPECIAL RESOLUTION

1. To consider and approve the resolution on the repurchase of the Company’s A Shares for cancellation and reduction of registered capital
 - 1.1 Purpose of the repurchase of A Shares
 - 1.2 The repurchase of A Shares meets relevant conditions
 - 1.3 Method and price range of the repurchase of A Shares
 - 1.4 Type, use, quantity, percentage and total funds of the repurchase of A Shares
 - 1.5 Source of funds for the repurchase of A Shares
 - 1.6 Implementation period of the repurchase of A Shares
 - 1.7 Authorisation in connection with the implementation of the repurchase of A Shares

NOTICE OF THE 2026 SECOND EXTRAORDINARY GENERAL MEETING

ORDINARY RESOLUTION

2. To consider and approve the amendments to the Remuneration Management Rules for Directors and Senior Management

By order of the Board
Cofoe Medical Technology Co., Ltd.
ZHANG Min
Executive Director and Chairman of the Board

Hong Kong, June 26, 2026

Notes:

1. ELIGIBILITY TO ATTEND THE EGM AND RECORD DATE FOR H SHAREHOLDERS

For the purpose of determining the entitlement of Shareholders to attend and vote at the EGM, the register of members of H Shares of the Company will be closed from July 14, 2026 to July 17, 2026 (both days inclusive), during which no transfer of H Shares will be effected.

Holders of H Shares who wish to attend the EGM should lodge all transfer documents accompanied by the relevant share certificates with the Company's H Share Registrar, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong, no later than 4:30 p.m. on July 13, 2026. The record date for determining the entitlement to attend and vote at the EGM will be July 17, 2026.

2. APPOINTMENT OF PROXIES

Any Shareholder entitled to attend and vote at the EGM may appoint one or more proxies in writing to attend and vote on his/her/its behalf. A proxy need not be a Shareholder of the Company.

- (i) The proxy form for the appointment of a proxy must be signed by the appointor or by his/her attorney duly authorised in writing, or, if the appointor is a legal entity, it must be executed under its seal or signed by its director or duly authorised attorney. If the proxy form is signed by an attorney of the appointor, the power of attorney or other authorisation document authorising such attorney to sign must be notarised.
- (ii) To be valid, the proxy form, together with the notarised power of attorney or other authorisation document, must be lodged with the Company's H Share Registrar, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong, not less than 24 hours before the time appointed for the holding of the EGM (i.e., by 3:00 p.m. on Thursday, July 16, 2026).

3. REGISTRATION PROCEDURES FOR ATTENDING THE EGM

Shareholders or their proxies shall produce proof of identity when attending the EGM. If the Shareholder is a legal entity, its legal representative or other person authorised by its board of directors or other decision-making body shall provide a copy of the resolution of such board or other decision-making body appointing such person to attend the meeting before being admitted to the EGM.

4. VOTING BY POLL

Pursuant to Rule 13.39(4) of the Hong Kong Listing Rules, any vote of Shareholders at a general meeting must be taken by poll. For the avoidance of doubt and for the purposes of the Hong Kong Listing Rules, holders of treasury shares shall abstain from voting on matters requiring Shareholders' approval at the Company's general meetings.

NOTICE OF THE 2026 SECOND EXTRAORDINARY GENERAL MEETING

5. OTHER MATTERS

(i) The EGM is expected to last no more than half a day. Shareholders attending the meeting in person or by proxy shall bear their own travelling and accommodation expenses.

(ii) The Company's registered office:

No. 87, Section 1, Huanbao East Road
Yuhua District
Changsha City, Hunan Province
PRC

Contact department: Securities Department of the Company
Tel: 0731-85506600
Email: tanxianming@cofoe.com
Contact person: TAN Xianming

As at the date of this notice, the Board of the Company comprises: (i) Mr. ZHANG Min, Mr. ZHANG Zhiming, Mr. XUE Xiaoqiao and Mr. HE Bangjie as executive directors; and (ii) Mr. NING Huabo, Ms. SHEN Nan and Mr. ZHOU Rong as independent non-executive directors.